Gefitinib, which is one of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), is widely used for patients with NSCLC, especially the ones harbor somatic mutations in the EGFR gene [12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.